Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL153717 | 0.89 | L3MBTL1 (0.42) | L3MBTL1EPHX1CYP1A2PKMPTK2B | |
| SCHEMBL13542985 | 0.78 | L3MBTL1 (0.39) | L3MBTL1CYP1A2PKMPTK2B | |
| SCHEMBL14040406 | 0.76 | KDM4C (0.45) | L3MBTL1CYP1A2PKMPTK2BPOLB | |
| SCHEMBL19964618 | 0.76 | EPHX1 (0.36) | EPHX1POLBMEN1KMT2A | |
| SCHEMBL6276759 | 0.76 | EPHX1 (0.36) | EPHX1POLBMEN1KMT2A | |
| SCHEMBL21137601 | 0.75 | KMT2A (0.36) | KMT2A | |
| SCHEMBL15079429 | 0.74 | L3MBTL1 (0.36) | L3MBTL1CYP1A2PKMPTK2B | |
| SCHEMBL18902033 | 0.74 | EPHX1 (0.34) | EPHX1POLBMEN1KMT2A | |
| SCHEMBL23095629 | 0.72 | L3MBTL1 (0.34) | L3MBTL1CYP1A2PKMPTK2B | |
| SCHEMBL17399505 | 0.72 | DGAT1 (0.39) | L3MBTL1CYP1A2PKMPTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-26 | — | — | US | disclosed |
| US-7524883-B2 | Eponemycin and epoxomicin analogs and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | PSMC4, PSMB6, EPOR | L3MBTL1 2058/4885EPHX1 463/4885CYP1A2 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.